Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting roughly half of all adults living with the disease over the course of their lifetime. It is also the single greatest contributor to foot ulceration, falls, and lower-extremity amputation. Yet DPN remains under-recognized in routine practice, partly because measurable nerve injury can be present years before a patient reports any symptoms. The past decade has seen meaningful progress in both how DPN is detected and how its painful and disabling features are treated. This post summarizes the evidence-based screening recommendations that anchor modern practice and reviews the pharmacologic and neuromodulatory options that are reshaping management.
Why Early Detection Matters
Loss of protective sensation (LOPS) is the strongest single predictor of diabetic foot ulceration, and ulceration precedes roughly 85% of nontraumatic lower-limb amputations in people with diabetes. Estimates from large observational cohorts place the lifetime risk of a diabetic foot ulcer at 19–34%, with substantial recurrence after healing. Because up to half of patients with documented DPN report no neuropathic symptoms, screening is essential to identify the at-risk foot before tissue is lost.
Modern Screening: The Annual Foot Exam
The American Diabetes Association Standards of Care in Diabetes—2024 reaffirm that every adult with diabetes should undergo a comprehensive foot examination at least annually, with more frequent assessment for those in higher-risk categories. Neurologic screening centers on the 10-g Semmes-Weinstein monofilament, which should always be paired with at least one additional test—pinprick, temperature perception, vibration with a 128-Hz tuning fork, or ankle reflexes. Two abnormal findings confirm LOPS and trigger a structured prevention plan that includes education, professional foot care, and appropriate footwear.
Going Beyond the Monofilament
The monofilament reliably detects established large-fiber loss but is insensitive to early or small-fiber neuropathy. Several techniques are now available in specialized centers to fill that gap. Quantitative sensory testing, sudomotor function assessment (electrochemical skin conductance), corneal confocal microscopy, and intraepidermal nerve fiber density on skin biopsy can each identify small-fiber dysfunction before traditional bedside testing turns positive. Recent reviews highlight these modalities as promising biomarkers for earlier diagnosis and as objective endpoints for clinical trials of disease-modifying therapy.
Pharmacologic Management of Painful DPN
Approximately one in four adults with diabetes develops painful DPN, characterized by burning, lancinating, or electric-shock-like discomfort that disrupts sleep and quality of life. Four agents are currently approved by the U.S. Food and Drug Administration specifically for painful DPN: pregabalin, duloxetine, tapentadol extended-release, and the 8% capsaicin topical system. The 2022 American Academy of Neurology practice guideline update recommends gabapentinoids (pregabalin, gabapentin), serotonin-norepinephrine reuptake inhibitors (duloxetine, venlafaxine), tricyclic antidepressants, and selected sodium-channel blockers as first-line options, while advising against routine use of oral opioids because of limited durable benefit and substantial harm.
The high-concentration 8% capsaicin patch represents a notable advance in topical therapy. A single 30-minute application desensitizes TRPV1-expressing cutaneous nociceptors and has been shown in randomized trials to provide meaningful pain relief for up to 12 weeks, with emerging evidence suggesting regeneration of cutaneous nerve fibers between treatments. Combination regimens (for example, a gabapentinoid plus an SNRI) are increasingly used when monotherapy fails to achieve adequate analgesia.
Emerging Therapies
Two areas of investigation are particularly promising. First, glucagon-like peptide-1 (GLP-1) receptor agonists, already established for glycemic and cardiovascular benefit in type 2 diabetes, are being examined for direct neuroprotective effects. Preclinical and early clinical data summarized in a 2023 review describe reductions in oxidative stress, inflammation, and extracellular matrix remodeling in peripheral nerve, with intriguing improvements in nerve conduction and small-fiber parameters.
Second, high-frequency 10-kHz spinal cord stimulation (SCS) has produced durable pain reduction in patients with refractory painful DPN. The Senza-PDN randomized trial demonstrated that more than three-quarters of treated patients achieved at least 50% pain relief at 6 and 12 months, with sustained improvements in neurologic examination findings and health-related quality of life. SCS now appears in several international guidelines as a consideration for patients whose pain is inadequately controlled with conventional pharmacotherapy.
Underlying all of these advances is the recognition that aggressive glycemic and multifactorial metabolic control remains the most effective disease-modifying intervention. Long-term follow-up of the Steno-2 study and meta-analyses of intensive glucose-lowering trials show that the largest reductions in neuropathy incidence come from treating glucose, blood pressure, and lipids together, particularly in type 2 diabetes.
Clinical Takeaways
DPN is common, frequently silent, and a principal driver of diabetic foot disease. Annual screening with the 10-g monofilament plus a second neurologic test remains the cornerstone of detection, and new small-fiber assessments are extending the diagnostic window. Treatment of painful DPN now rests on a defined set of first-line oral and topical agents, with high-frequency spinal cord stimulation offering a meaningful option for refractory disease. The strongest evidence for slowing or preventing neuropathy itself continues to support intensive, multifactorial control of diabetes and its associated cardiovascular risk factors.
References
- ElSayed NA, Aleppo G, Aroda VR, et al. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S231–S243.
- Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: Practice guideline update summary. Neurology. 2022;98(1):31–43.
- Galiero R, Caturano A, Vetrano E, et al. Diabetic Peripheral Neuropathy: Emerging Treatments of Neuropathic Pain and Novel Diagnostic Methods. Life (Basel). 2024.
- Petersen EA, Stauss TG, Scowcroft JA, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-month results of a randomized controlled trial. Diabetes Research and Clinical Practice. 2022;189:109928.
- Yang X, Qiang Q, Li N, et al. Glucagon-like peptide-1 receptor agonists for the management of diabetic peripheral neuropathy. Frontiers in Endocrinology. 2023;14:1268619.
- Gaede P, Oellgaard J, Carstensen B, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–2307.
Comments
